Docetaxel

Country: Nýja-Sjáland

Tungumál: enska

Heimild: Medsafe (Medicines Safety Authority)

Virkt innihaldsefni:

Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg

Fáanlegur frá:

REX Medical Ltd

INN (Alþjóðlegt nafn):

Docetaxel trihydrate 25.177 mg (equivalent to anhydrous docetaxel 20mg)

Skammtar:

20 mg/mL

Lyfjaform:

Concentrate for infusion

Samsetning:

Active: Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Einingar í pakka:

Vial, glass, Diluent, 1.5 mL

Tegund:

Prescription

Gerð lyfseðils:

Prescription

Framleitt af:

Cipla Ltd

Ábendingar:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Vörulýsing:

Package - Contents - Shelf Life: Vial, glass, Diluent - 1.5 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 20 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Leyfisdagur:

2006-06-23